Clinical Trials Directory

Trials / Completed

CompletedNCT07189832

Bleomycin Intralesional Injections of Cystic Hygromas

Bleomycin Intralesional Injections of Cystic Hygromas in Pediatric Patients

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
30 (actual)
Sponsor
Delta University for Science and Technology · Academic / Other
Sex
All
Age
1 Month – 12 Years
Healthy volunteers
Accepted

Summary

Thirty pediatric patients with cystic hygromas participated in this study. The cystic fluid was aspirated from the cystic hygroma, and the lesion was simultaneously injected with Bleomycin. Then, the lesion was re-injected at 4-week intervals until satisfactory results were obtained. Clinical response was evaluated as complete response (\> 90% reduction of lesion size), marked improvement (\>70% reduction of lesion size), moderate improvement (40 - 70% reduction of lesion size), slight improvement (\< 40%), and no response (\< 10% reduction of lesion size).

Detailed description

A total of 30 pediatric patients of age up to 12 years having Cervicofacial cystic hygromas (macrocystic lymphatic malformations) were chosen from the vascular anomalies clinic in Cairo University Specialized Pediatric Hospital (CUSPH). Diagnosis was accomplished by taking history from parents, clinical examination, and confirmed by ultrasonography (USG) and\\or magnetic resonance imaging (MRI) for deep lesions. The procedure was explained in simple, clear words to the parents of each infant/child before the study, and an informed written consent was signed by each parent, containing treatment benefits, potential risks as outlined in the principles of Helsinki Declaration. Each infant/child was treated and followed up for 12 months after the last BLM intralesional injection.

Conditions

Interventions

TypeNameDescription
PROCEDUREIntralesional InjectionsIntralesional Injections

Timeline

Start date
2024-09-01
Primary completion
2025-04-01
Completion
2025-04-01
First posted
2025-09-24
Last updated
2025-11-24

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT07189832. Inclusion in this directory is not an endorsement.